JP2025511391A5 - - Google Patents

Info

Publication number
JP2025511391A5
JP2025511391A5 JP2024559019A JP2024559019A JP2025511391A5 JP 2025511391 A5 JP2025511391 A5 JP 2025511391A5 JP 2024559019 A JP2024559019 A JP 2024559019A JP 2024559019 A JP2024559019 A JP 2024559019A JP 2025511391 A5 JP2025511391 A5 JP 2025511391A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
domain
domain contains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024559019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511391A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/065290 external-priority patent/WO2023196786A1/en
Publication of JP2025511391A publication Critical patent/JP2025511391A/ja
Publication of JP2025511391A5 publication Critical patent/JP2025511391A5/ja
Pending legal-status Critical Current

Links

JP2024559019A 2022-04-04 2023-04-03 抗デクチン-1抗体及びその使用方法 Pending JP2025511391A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263327288P 2022-04-04 2022-04-04
US63/327,288 2022-04-04
PCT/US2023/065290 WO2023196786A1 (en) 2022-04-04 2023-04-03 Anti-dectin-1 antibodies and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2025511391A JP2025511391A (ja) 2025-04-15
JP2025511391A5 true JP2025511391A5 (cg-RX-API-DMAC7.html) 2026-04-10

Family

ID=88243583

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024559019A Pending JP2025511391A (ja) 2022-04-04 2023-04-03 抗デクチン-1抗体及びその使用方法

Country Status (10)

Country Link
US (2) US20250230247A1 (cg-RX-API-DMAC7.html)
EP (1) EP4504794A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025511391A (cg-RX-API-DMAC7.html)
KR (1) KR20250006353A (cg-RX-API-DMAC7.html)
CN (1) CN119301156A (cg-RX-API-DMAC7.html)
AU (1) AU2023251034A1 (cg-RX-API-DMAC7.html)
CA (1) CA3255392A1 (cg-RX-API-DMAC7.html)
IL (1) IL315845A (cg-RX-API-DMAC7.html)
MX (1) MX2024012194A (cg-RX-API-DMAC7.html)
WO (1) WO2023196786A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
KR20240170833A (ko) * 2022-04-04 2024-12-04 드렌 바이오, 인크. 덱틴-1 및 cd20에 결합하는 다중특이성 결합 단백질 및 이의 사용 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202110663UA (en) * 2019-04-05 2021-10-28 Dren Bio Inc Methods of depleting disease causing agents via antibody targeted phagocytosis
EP4225373A4 (en) * 2020-10-07 2025-01-08 Dren Bio, Inc. ANTI-DECTIN-1 ANTIBODIES AND METHODS OF USE THEREOF

Similar Documents

Publication Publication Date Title
JP2023545057A5 (cg-RX-API-DMAC7.html)
US12398207B2 (en) Heterodimeric antibodies that bind CD3 and CLDN6
JP7058219B2 (ja) Cd3及びpsmaに結合するヘテロ二量体抗体
ES2439802T3 (es) Anticuerpos tri- o tetraespecíficos
JP2018183173A5 (cg-RX-API-DMAC7.html)
MX2011013616A (es) Proteinas biespecificas tetravalentes de union a antigeno.
US12404329B2 (en) Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
AU2018387829B2 (en) Bispecific antigen binding construct
JP2022529154A5 (cg-RX-API-DMAC7.html)
US20240279356A1 (en) Heterodimeric antibodies that bind msln and cd3
US20230151095A1 (en) Bispecific antibodies that bind to b7h3 and nkg2d
JP2024541680A5 (cg-RX-API-DMAC7.html)
AU2023353699A1 (en) Multispecific antibodies and methods of use thereof
US20250243279A1 (en) Bispecific antibodies that bind to nkp46 and mica/b
CA3255392A1 (en) Anti-Dectin-1 Antibodies and Their Methods of Use
US20240150471A1 (en) Natural killer cell antibodies with increased adcc activity
US20240034815A1 (en) Heterodimeric antibodies that bind cd3 and gpc3
US20240360220A1 (en) Orthogonal multimeric proteins
WO2026080752A2 (en) De novo antibodies to activin a receptor like type 1 (alk1)
WO2025024780A1 (en) Antibodies that bind gamma-delta t cell receptors for the treatment of cancer